Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | CCR6 | P51684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29959951 | 1.00 | ESR1 (0.42) | ESR1S1PR1CYP1A2SMN1; SMN2MEN1 | |
| SCHEMBL8169667 | 0.83 | ALDH1A1 (0.38) | CYP1A2MEN1KMT2AKDM4ETSHR | |
| SCHEMBL8588110 | 0.80 | — | — | |
| SCHEMBL5139053 | 0.79 | ESR1 (0.39) | ESR1S1PR1CYP1A2SMN1; SMN2MEN1 | |
| SCHEMBL9435737 | 0.78 | ALDH1A1 (0.38) | CYP1A2MEN1KMT2AKDM4ETSHR | |
| SCHEMBL10786761 | 0.78 | ALOX15 (0.35) | ESR1S1PR1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL31116625 | 0.76 | TSHR (0.48) | ESR1MEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL305842 | 0.76 | TSHR (0.48) | ESR1MEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL39946 | 0.75 | ESR1 (0.44) | ESR1S1PR1CYP1A2SMN1; SMN2MEN1 | |
| SCHEMBL9818045 | 0.75 | ESR1 (0.44) | ESR1S1PR1CYP1A2SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 328 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110511521-A | A kind of polyallyl benzamide-graphene hydrogel and its preparation method | ZHANG GUIYONG | 2019-11-29 | — | — | CN | claimed |
| CN-110194739-A | A kind of cyanoalkyl substituted-dihydro isoquinolinone compound and preparation method thereof | 江苏理工学院 | 2019-09-03 | — | — | CN | claimed |
| CN-110041367-A | Photocatalytic synthesis is at phosphonylation dihydro-isoquinoline ketone compounds | 郑州大学 | 2019-07-23 | — | — | CN | claimed |
| CN-110003274-A | Phosphonylation dihydro-isoquinoline ketone compounds and preparation method thereof | 郑州大学 | 2019-07-12 | — | — | CN | claimed |
| CN-109734662-A | A kind of trifluoromethyl substituted-dihydro isoquinolinone derivatives and preparation method thereof | 郑州大学 | 2019-05-10 | — | — | CN | claimed |
| EP-1512397-B1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INST MED MOLECULAR DESIGN INC (JP) | 2014-10-08 | — | — | EP | claimed |
| US-8067419-B2 | N-[(S)-1-benzyl-2-(4-benzyl-piperazin-1-yl)-2-oxo-ethyl]-N-(4-pentyl-benzyl)-3-(4-trifluoromethyl-phenyl)-acrylamide, for example; antiprotozoa agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-29 | — | — | US | claimed |
| JP-4815083-B2 | — | — | 2011-11-16 | — | — | JP | claimed |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-05-06 | — | — | US | claimed |
| US-20100075966-A1 | Substituted Dihydroimidazoles and their Use in the Treatment of Tumors | NOVARTIS AG | 2010-03-25 | — | — | US | claimed |
| US-4655816-A | PLANT GROWTH REGULATORS | MONSANTO COMPANY (US) | 1987-04-07 | — | — | US | claimed |
| EP-0102318-B1 | PREPARATION OF BETA-AMINO-ALPHA,BETA-UNSATURATED CARBOXYLIC-ACID ESTERS | CIBA-GEIGY AG (CH) | 1987-01-14 | — | — | EP | claimed |
| US-4619991-A | DIAZOTIZATION COUPLING DEHYDRATION OF 1,2,3-TRIAZOLE COMPOUND | SANDOZ LTD. (CH) | 1986-10-28 | — | — | US | claimed |
| EP-0190105-A2 | Herbicidal agent | CIBA-GEIGY AG (CH) | 1986-08-06 | — | — | EP | claimed |
| US-4439562-A | Polymeric material mass-dyed with certain metalized bis-azomethine dyestuffs | SANDOZ LTD. (CH) | 1984-03-27 | — | — | US | claimed |
| US-4395544-A | DYES OR CHEMICAL INTERMEDIATES FOR DYESTUFFS | SANDOZ LTD. (CH) | 1983-07-26 | — | — | US | claimed |
| US-4362879-A | Isothioureido isoindolediones and use as plant growth regulators | GULF OIL CORPORATION (US) | 1982-12-07 | — | — | US | claimed |
| US-4341700-A | Monoazo compounds having a substituted 1,2,3-triazolyl-5 diazo component radical and an unsubstituted or substituted 1,4-phenylene coupling component radical | SANDOZ LTD. (CH) | 1982-07-27 | — | — | US | claimed |
| US-4218372-A | Azo compounds having a β-alkynyloxy carbonylalkyl group on the coupling component radical | SANDOZ LTD. (CH) | 1980-08-19 | — | — | US | claimed |
| US-4157333-A | CONDENSATION OF 1,2-METHYLENEDIOXYBENZENE WITH N-ALKYLOORMANILIDE, HYDROLYSIS | MITSUI TOATSU CHEMICALS, INC. (JP) | 1979-06-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075966-A1 | Substituted Dihydroimidazoles and their Use in the Treatment of Tumors | TP53, KRAS, NRAS | ESR1 3673/4885S1PR1 3794/4885CYP1A2 3419/4885 |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | RELA, NFKBIA, NFE2 | ESR1 1135/4885S1PR1 4191/4885CYP1A2 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.